Drug Trial Radar · NCT06812078
A Study of TAK-360 in Adults With Idiopathic Hypersomnia
Last checked: Nov 19, 2026Latest source record: Jul 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
96
Planned (sponsor's estimate)
Start
Feb 7, 2025
Primary completion
Nov 30, 2026
Study completion Nov 30, 2026
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Feb 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Idiopathic Hypersomnia (IH) is a condition where people feel extremely sleepy during the day, especially in the morning, even if they sleep a lot at night. They may have trouble waking up in the morning, no matter how much they sleep (sometimes more than 11 hours per day), and they can't help feeling tired, even after taking daytime naps. Because of this sleepiness, they may have trouble focusing, thinking clearly, or keeping up with daily activities. They may also have symptoms like dizziness or feeling lightheaded. Orexin is a chemical made in the brain that helps keep a person awake and alert. TAK-360 acts like orexin. Previous studies have shown that medicines that act like orexin may keep people awake. The main aim of this study is to learn how safe TAK-360 is and how well adults with IH tolerate it. Researchers also want to find out if TAK-360 can help people with IH stay awake and how much TAK-360 is needed to do that. Participants will be randomly (by chance, like drawing names from a hat) chosen to receive either TAK-360 or a placebo. The placebo looks just like TAK-360 but does not have any medicine in it. Using a placebo helps researchers learn about the real effect of the treatment.
Conditions
- Idiopathic Hypersomnia
Interventions
TAK-360Drug
TAK-360 tablet.
PlaceboOther
TAK-360 matching placebo tablet.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With at Least One Treatment-emergent Adverse Events (TEAEs)Time frame: Up to Week 8
Locations
29 sites in 6 countries. Site status is shown where the registry gives one.
Takeda Site 11
Redwood City, California · Recruiting
Takeda Site 10
Santa Ana, California · Recruiting
Takeda Site 27
Colorado Springs, Colorado · Recruiting
Takeda Site 19
Brandon, Florida · Recruiting
Takeda Site 14
Winter Park, Florida · Recruiting
Takeda Site 29
St Louis, Missouri · Recruiting
Takeda Site 16
Denver, North Carolina · Recruiting
Takeda Site 15
Huntersville, North Carolina · Recruiting
Takeda Site 12
Cincinnati, Ohio · Recruiting
Takeda Site 17
Cincinnati, Ohio · Recruiting
Takeda Site 13
Columbia, South Carolina · Recruiting
Takeda Site 18
San Antonio, Texas · Recruiting
Takeda Site 28
Norfolk, Virginia · Recruiting
Takeda Site 2
Paris, France · Recruiting
Takeda Site 1
Montpellier, Hrault, France · Recruiting
Takeda Site 3
Nantes, Pays de Loire, France · Recruiting
Takeda Site 4
Shatin, Hong Kong · Withdrawn
Takeda Site 5
Bologna, Italy · Recruiting
Takeda Site 6
Pozzilli, Isernia, Italy · Recruiting
Takeda Site 7
Rome, Roma, Italy · Recruiting
Takeda Site 26
Verona, Veneto, Italy · Recruiting
Takeda Site 25
Fukuoka-Shi Hakata-Ku, Fukuoka, Japan · Recruiting
Takeda Site 23
Kurume-shi, Fukuoka, Japan · Recruiting
Takeda Site 22
Kohoku-ku, Yokohama-Shi, Kanagawa, Japan · Recruiting
Takeda Site 20
Kumamoto, Kumamoto, Japan · Recruiting
Takeda Site 21
Yodogawa-ku, Osaka-shi, Osaka, Japan · Recruiting
Takeda Site 24
Bunkyo-ku, Tokyo, Japan · Recruiting
Takeda Site 8
Madrid, Spain · Recruiting
Takeda Site 9
Vitoria-Gasteiz, Alava, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.